Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 83 TO2 | DOI: 10.1530/endoabs.83.TO2

EYES2022 ESE Young Endocrinologists and Scientists (EYES) 2022 Thyroid (12 abstracts)

Subacute thyroiditis (SAT) during the COVID-19 pandemic: preliminary data from the “ESE Covid Grant 2021” project

Zanni E.1, 2, Loiacono S.1, 2, Sueri R.1, 2, Cecchetti C3, Crivicich E4, Di Marco F4, Muller I.5, 6, Tucci L3, De Vincentis S.1, 2, Monzani M. L.1, 2, Simoni M.1, 2, Santi D.1, 2 & Brigante G.1, 2


1 University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences; 2Azienda Ospedaliero-Universitaria of Modena, Unit of Endocrinology, Department of Medical Specialties; 3Azienda Ospedaliero-Universitaria of Bologna, Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC); 4University of Milan, School of Specialisation in Endocrinology; 5University of Milan, Department of Clinical Sciences and Community Health; 6Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Endocrinology


Background: A possible association between severe acute respiratory syndrome coronavirus (SARS-CoV)-2 pandemic and subacute thyroiditis (SAT) has been reported.

Objectives: To evaluate SAT clinical characteristics, correlating them to virus exposure and/or vaccine and to evaluate thyroid function according to the length of time after symptoms onset.

Methods: We performed a prospective, observational, multi-centre study, considering three Italian centres. Patients with documented SAT diagnosis were enrolled from November 2020 to May 2022 and followed up for 12 months. SARS-CoV-2 infection (i.e. positive rhino-pharyngeal swab obtained within 3 months before SAT onset) and vaccination were recorded. This interim analysis was performed considering the visit performed at diagnosis.

Results: A total of 67 subjects (79.1% F, 20.9% M) were enrolled (age: 49.9+12.9 years). The cohort was divided considering the time between symptoms onset and endocrinological evaluation: Group1 included patients who underwent visit within 15 days (44.8%), whereas Group2 those who delayed visit beyond 15 days (55.2%). No difference in inflammation indexes and thyrotoxicosis rate (70.0% vs 70.3%, P = 0.381) was found between groups. Hypothyroidism rate was higher in Group2 than in Group1 (8.1% vs 0.0%, P = 0.004). The entire cohort was divided according to either SARS-Cov2 infection (13 patients–19.4%) or vaccination (23 patients–34.3%). Thyrotoxicosis rate and inflammation indexes were not significantly different between patients with or without SARS-Cov2 infection and/or vaccination. At multinomial logistic regression analyses, thyrotoxicosis was predicted by erythrocyte sedimentation rate (ESR) elevation (P < 0.001), SARS-CoV-2-vaccination (P = 0.002) and respiratory symptoms (P < 0.001).

Conclusions: Neither SARS-CoV-2 infection nor vaccination affected the clinical SAT presentation. However, SAT-related thyrotoxicosis was predicted by ESR elevation, vaccination, and respiratory symptoms.

Volume 83

ESE Young Endocrinologists and Scientists (EYES) 2022

Zagreb, Croatia
02 Sep 2022 - 04 Sep 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.